The generation of induced pluripotent stem cell (iPSC) models involves reprogramming of somatic cells into a pluripotent state while retaining the genetic background. The iPSC models can then be differentiated into specific cell types to, for example, study cellular differentiation or cell type specific biology. Moreover, iPSC models can be generated from patient-derived somatic cells and differentiated into specific cell types affected by a particular disease, allowing researchers to model and study the disease in a controlled laboratory setting. In combination with CRISPR screens, iPSC-derived disease models provide a valuable tool to systematically investigate the effects of gene perturbation on disease-related phenotypes, which can yield insights into disease mechanisms and potential therapeutic targets.

In addition, iPSC models combined with CRISPR screens offer a platform for drug discovery and toxicity testing. Researchers can use iPSCs to generate disease-relevant cell types and perform CRISPR screens to identify genes or pathways that modulate drug responses. This information can guide the development of targeted therapies and help identify potential off-target effects or drug toxicity. 

iPSC models provide a renewable and ethically sound source of human cells for these studies, reducing the reliance on animal models and enhancing the translational potential of the findings.